Dyne Therapeutics, Inc. (NASDAQ:DYN) Insider Oxana Beskrovnaya Sells 2,334 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Oxana Beskrovnaya sold 2,334 shares of Dyne Therapeutics stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $65,632.08. Following the sale, the insider now owns 201,685 shares in the company, valued at $5,671,382.20. The trade was a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Oxana Beskrovnaya also recently made the following trade(s):

• On Wednesday, September 18th, Oxana Beskrovnaya sold 2,339 shares of Dyne Therapeutics stock. The stock was sold at an average price of $34.55, for a total value of $80,812.45.

Dyne Therapeutics Stock Down 3.0 %

DYN stock opened at $27.47 on Thursday. The firm has a market capitalization of $2.80 billion, a PE ratio of -7.72 and a beta of 1.09. Dyne Therapeutics, Inc. has a twelve month low of $10.33 and a twelve month high of $47.45. The stock has a 50-day simple moving average of $30.68 and a two-hundred day simple moving average of $35.30.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). On average, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3.45 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on DYN. StockNews.com cut Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. Stifel Nicolaus lifted their target price on Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Royal Bank of Canada initiated coverage on Dyne Therapeutics in a report on Tuesday, November 26th. They issued an “outperform” rating and a $45.00 price objective for the company. Morgan Stanley lifted their price objective on Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Finally, Guggenheim lifted their price objective on Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $50.82.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. State of New Jersey Common Pension Fund D purchased a new position in shares of Dyne Therapeutics during the third quarter worth about $1,588,000. Seven Eight Capital LP grew its holdings in shares of Dyne Therapeutics by 195.7% during the second quarter. Seven Eight Capital LP now owns 53,739 shares of the company’s stock worth $1,896,000 after purchasing an additional 35,568 shares in the last quarter. Jennison Associates LLC grew its holdings in shares of Dyne Therapeutics by 1.5% during the third quarter. Jennison Associates LLC now owns 1,346,952 shares of the company’s stock worth $48,383,000 after purchasing an additional 19,730 shares in the last quarter. Mutual of America Capital Management LLC bought a new stake in Dyne Therapeutics in the 2nd quarter worth approximately $1,724,000. Finally, Victory Capital Management Inc. bought a new stake in Dyne Therapeutics in the 2nd quarter worth approximately $676,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.